Copanlisib+Rituximab Shows Promise for Some Lymphomas

According to the American Society of Hematology (ASH), findings from phase III of the CHRONOS-3 trial testing a combination therapy using copanlisib and rituximab reduced the risk of progression or death by 48% compared with rituximab alone. The study was open to participants who had relapsed Indolent B-cell Non-Hodgkin’s Lymphoma, including follicular lymphoma, small lymphocytic…… Continue reading Copanlisib+Rituximab Shows Promise for Some Lymphomas